XML 27 R19.htm IDEA: XBRL DOCUMENT
v3.22.2.2

SHARE CAPITAL | 6 Months Ended
--- | ---
Jun. 30, 2022
SHARE CAPITAL |
SHARE CAPITAL | 14.SHARE CAPITAL ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of
​ | ​ | June 30, 2022 | ​ | December 31, 2021
​ |  | Number |  | US$ |  | Number |  | US$
​ | ​ | of shares | ​ | ‘000 | ​ | of shares | ​ | ‘000
Authorized: |  |  |  |  |  |  |  |
Ordinary shares of US$ 0.024 each |  | 50,000,000 |  | 1,200 |  | 50,000,000 |  | 1,200
​
​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​
​ | ​ | June 30, 2022
​ |  | Number |  | RMB
​ | ​ | of shares | ​ | ‘000
Outstanding and fully paid: |  |  |  |
Ordinary shares of US$ 0.024 each |  |  |  |
At January 1, 2022 |  | 5,976,098 |  | 943
Issuance of new shares for equity financing |  | — |  | —
Warrants exercised |  | — |  | —
Issuance of new shares – share-based compensation to CEO and CFO |  | 132,231 |  | 21
At June 30, 2022 |  | 6,108,329 |  | 964
​ On February 12, 2021, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale of 588,235 common shares, at a purchase price of $3.57 per share. Concurrently with the sale of the Common Shares, pursuant to the Purchase Agreement the Company also sold warrants to purchase 588,235 common shares. The Company sold the Common Shares and Warrants for aggregate gross proceeds of approximately US$2.1 million, before commissions and expenses. The five-year Warrants will be immediately exercisable at an exercise price equal to $3.57 per share, and will terminate on the five-year anniversary of the initial exercise date of the Warrants. The net proceeds from the transactions will be approximately US$1.86 million, after deducting certain fees due to the placement agent and the Company’s estimated transaction expenses, and will be used for working capital and general corporate purposes. In addition, the Placement Agent of this offering also received five-year warrants (the “Compensation Warrants”) to purchase up to a number of common shares equal to 5% of the aggregate number of shares sold in the Offering, including the warrant shares issuable upon exercise of the Warrants, which such Compensation Warrants have substantially the same terms as the Warrants sold in the Offering, except that such Compensation Warrants have an exercise price of $4.46 per share and will be exercisable six months from the effective date of this offering and will terminate on the five year anniversary of the effective date of this offering. ​
​ | ​ | ​ | ​ | ​
​ |  | ​ | February 17, | ​
Grant date (investors and placement agent, respectively) | ​ | ​ | 2021 | ​
Share price at date of grant (investors and placement agent, respectively) |  | US$ | 4.45 | ​
Exercise price at date of grant (investors and placement agent, respectively) |  | US$ | 3.57 & 4.46 | ​
Volatility |  | ​ | 107 | %
Warrant life |  | ​ | 5 years | ​
Dividend yield |  | ​ | 0 | %
Risk-free interest rate |  | ​ | 0.57 | %
Average fair value at grant date |  | US$ | 3.54 | ​
​ On June 10, 2021, the Company commenced a registered direct offering of securities, and executed a Securities Purchase Agreement (“SPA”) with three institutional accredited investors pursuant to which it sold 913,875 of the Company’s common shares at the per share price of $3.48 (which was priced in excess of the average of the five-day closing price for the Company’s common shares preceding execution of the SPA, which was $3.42). In a concurrent private placement, the Company sold to such investors warrants to purchase 913,875 common shares (the “Investor Warrants”). The Investor Warrants have an exercise price per share of $3.42, subject to adjustment, and have a term of five years. The transactions yielded gross proceeds to the Company of $3,180,285, before the payment of commissions and expenses. In addition, the Company issued warrants (the “Placement Agent Warrants”) to the Placement Agent to purchase a number of common shares equal to 5.0% of the aggregate number of shares sold to the investors in this offering, as well as the warrant shares issuable upon exercise of the Warrants issued in the concurrent private placement, as additional placement agency compensation. The Placement Agent Warrants have substantially the same terms as the Investor Warrants, except that the Placement Agent Warrants will have an exercise price of $4.35. ​
​ | ​ | ​ | ​ | ​
Grant date (investors and placement agent, respectively) |  | ​ | June 14, 2021 | ​
Share price at date of grant (investors and placement agent, respectively) |  | US$ | 3.15 | ​
Exercise price at date of grant (investors and placement agent, respectively) |  | US$ | 3.42 & 4.35 | ​
Volatility |  | ​ | 115 | %
Warrant life |  | ​ | 5 years | ​
Dividend yield |  | ​ | 0 | %
Risk-free interest rate |  | ​ | 0.80 | %
Average fair value at grant date |  | US$ | 2.50 | ​
​ Following is a summary of the warrant activity for the six months ended June 30, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ | ​ |  | Weighted
​ | ​ | ​ | ​ | ​ | ​ | ​ | Average
​ | ​ | ​ | ​ | ​ | ​ | ​ | Remaining
​ | ​ | ​ | ​ | Average | ​ | Contractual
​ | ​ | Number of | ​ | Exercise | ​ | Term in
​ | ​ | Warrants | ​ | Price | ​ | Years
Outstanding at December 31, 2021 |  | 1,868,414 | ​ | $ | 3.50 |  | 4.14
Exercisable at December 31, 2021 |  | 1,868,414 | ​ | ​ | 3.50 |  | 4.14
Issued |  | — | ​ | ​ | — |  | —
Exercised |  | — | ​ |  | — |  | —
Expired |  | — | ​ |  | — |  | —
Outstanding at June 30, 2022 |  | 1,868,414 | ​ | ​ | 3.50 |  | 3.65
Exercisable at June 30, 2022 |  | 1,868,414 | ​ | $ | 3.50 |  | 3.65
​ From January 1 to June 30, 2022, the Company issued an aggregate of 41,742 shares to its Chief Financial Officer as stock compensation expense. The fair value of 41,742 shares was RMB 301,404. From January 1 to June 30, 2022, the Company issued aggregate of 90,489 shares to its Chief Executive Officer as stock compensation expense. The fair value of 90,489 shares was RMB 723,395.

X
- References No definition available. + Details
Name: | aehl_DisclosureOfShareCapitalAbstract
Namespace Prefix: | aehl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of issued capital. [Refer: Issued capital] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfIssuedCapitalExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration